
Sign up to save your podcasts
Or


For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EDR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until September 28, 2026.
Maximizing the Potential and Expanding the Impact of Immunotherapy in Advanced NSCLC
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.
Disclosure information is available at the beginning of the video presentation.
By PVI, PeerView Institute for Medical Education4.5
1010 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EDR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until September 28, 2026.
Maximizing the Potential and Expanding the Impact of Immunotherapy in Advanced NSCLC
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.
Disclosure information is available at the beginning of the video presentation.

1,794 Listeners

319 Listeners

40 Listeners

28 Listeners

10 Listeners

532 Listeners

5 Listeners

4 Listeners

2 Listeners

4 Listeners

2 Listeners

3 Listeners

5 Listeners

5 Listeners

2 Listeners

0 Listeners

9 Listeners

2 Listeners

116 Listeners

12 Listeners

2 Listeners

4 Listeners

57 Listeners

3 Listeners

5 Listeners

289 Listeners

21 Listeners

191 Listeners

53 Listeners

57 Listeners

49 Listeners

185 Listeners

43 Listeners